Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689798 | 0.82 | HSD17B10 (0.53) | KDM4ELMNADRD2ALDH1A1HSD17B10 | |
| SCHEMBL1057317 | 0.81 | ADRB1 (0.52) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL22887 | 0.75 | KDM4E (0.46) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL28396664 | 0.73 | ADRB1 (0.71) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL5846178 | 0.72 | HCRTR2 (0.47) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL9565835 | 0.72 | KDM4E (0.66) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL30407939 | 0.69 | ADRB1 (0.65) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL1825806 | 0.69 | ADRB1 (0.65) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL22663406 | 0.69 | KDM4E (0.50) | KDM4ELMNAADRB1DRD2DRD3 | |
| SCHEMBL424507 | 0.69 | DRD2 (0.75) | KDM4ELMNAADRB1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362374-A | Method for protecting hydroxyl and amino in compound containing hydroxyl and amino | 天津兴博润生物制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-7022833-B2 | Process for the preparation of phosphorothioate triesters | AVECIA LIMITED (GB) | 2006-04-04 | — | — | US | disclosed |
| EP-1272501-B1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | AVECIA LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030099981-A1 | Process for the preparation of phosphorothioate triesters | NITTO DENKO AVECIA, INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1272501-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | Avecia Limited (GB) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064702-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | AVECIA LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099981-A1 | Process for the preparation of phosphorothioate triesters | OSGEP, NUDT1, PNKP | KDM4E 4015/4885LMNA 2930/4885ADRB1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.